Verrica Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	5.12	9.03	12	0	0	0	0	0
Revenue Growth (YoY)	-43.27%	-24.73%	-	-	-	-	-	-
Cost of Revenue	0.75	0.73	0	0	0	0	0	0
Gross Profit	4.38	8.31	12	0	0	0	0	0
Selling, General & Admin	47.31	17.41	26.98	24.51	14.64	9.05	0.73	0.2
Research & Development	20.3	12.2	15.93	15.67	15.44	12.83	3.73	1.71
Other Operating Expenses	2.54	0	0	0	0	0	0	0
Operating Expenses	70.14	29.6	42.91	40.18	30.08	21.88	4.46	1.91
Operating Income	-65.76	-21.3	-30.91	-40.18	-30.08	-21.88	-4.46	-1.91
Interest Expense / Income	3.96	2.17	4.3	3.03	0	0	0	0
Other Expense / Income	-2.73	1.02	-0.12	-0.52	-1.87	-1.23	-0	-
Pretax Income	-67	-24.49	-35.08	-42.69	-28.21	-20.65	-4.46	-1.91
Net Income	-67	-24.49	-35.08	-42.69	-28.21	-20.65	-4.46	-1.91
Preferred Dividends	0	0	0	0	0	0	5.3	0
Net Income Common	-67	-24.49	-35.08	-42.69	-28.21	-20.65	-9.76	-1.91
Shares Outstanding (Basic)	45	34	27	25	25	15	3	6
Shares Outstanding (Diluted)	45	34	27	25	25	15	3	6
Shares Change	32.72%	26.32%	8.20%	0.39%	69.80%	414.43%	-54.87%	-
EPS (Basic)	-1.48	-0.72	-1.30	-1.71	-1.13	-1.41	-1.56	-0.30
EPS (Diluted)	-1.48	-0.72	-1.30	-1.71	-1.13	-1.41	-1.56	-0.30
Free Cash Flow	-38.94	-18.95	-28.47	-31.68	-28.09	-18.65	-4.58	-1.61
Free Cash Flow Per Share	-0.86	-0.56	-1.05	-1.27	-1.13	-1.27	-1.61	-0.26
Gross Margin	85.44%	91.97%	100.00%	-	-	-	-	-
Operating Margin	-1283.35%	-235.78%	-257.57%	-	-	-	-	-
Profit Margin	-1307.47%	-271.11%	-292.33%	-	-	-	-	-
Free Cash Flow Margin	-759.93%	-209.83%	-237.21%	-	-	-	-	-
EBITDA	-62.2	-21.6	-30.31	-39.43	-27.95	-20.63	-4.46	-1.91
EBITDA Margin	-1213.84%	-239.12%	-252.61%	-	-	-	-	-
Depreciation & Amortization	0.84	0.72	0.47	0.23	0.26	0.02	0	0
EBIT	-63.03	-22.32	-30.79	-39.66	-28.21	-20.65	-4.46	-1.91
EBIT Margin	-1230.15%	-247.07%	-256.54%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).